Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1441-7. doi: 10.1161/ATVBAHA.113.301273. Epub 2013 Apr 11.
Transthyretin can cause amyloidosis attributable to destabilization of transthyretin tetramers in plasma. We tested the hypothesis that genetic stabilization of transthyretin associates with reduced risk of vascular disease and increased life expectancy.
We included 68 602 participants from 2 prospective studies of the general population. We genotyped for 2 stabilizing genetic variants in the transthyretin gene (TTR), R104H and T119M, and determined the association of genotypes with plasma levels of transthyretin, measures of thyroid function, risk of vascular disease, and life expectancy. During a mean follow-up of 32 years, 10 636 participants developed vascular disease. We identified 321 heterozygotes for T119M (frequency, 0.47%); R104H was not detected. First, mean plasma transthyretin and thyroxine levels were increased by 17% (26 µg/mL) and 20% (19 nmol/L), respectively, in heterozygotes versus noncarriers (P=0.007 and P<0.0001), demonstrating functionality of this variant in the general population. Second, corresponding hazard ratios were 0.70 (95% confidence interval, 0.51-0.97) for all vascular diseases, 0.85 (0.59-1.23) for cardiovascular disease, 0.45 (0.25-0.81) for cerebrovascular disease, 0.47 (0.25-0.88) for ischemic cerebrovascular disease, and 0.31 (0.04-2.22) for hemorrhagic stroke. The cumulative incidence of cerebrovascular disease as a function of age was decreased in heterozygotes versus noncarriers (P=0.005). Third, median age at death from all causes, from vascular and cerebrovascular diseases, and after diagnosis of vascular disease, and median age at diagnosis of vascular disease, was increased by 5 to 10 years in heterozygotes versus noncarriers (P=0.002-0.05).
These results are compatible with an association between genetic stabilization of transthyretin and decreased risk of cerebrovascular disease, and with increased life expectancy in the general population.
转甲状腺素蛋白在血浆中四聚体的不稳定性可导致转甲状腺素蛋白淀粉样变性。我们检验了这样一个假说,即转甲状腺素蛋白的遗传稳定性与降低血管疾病风险和延长预期寿命相关。
我们纳入了两项普通人群前瞻性研究中的 68602 名参与者。我们对转甲状腺素蛋白基因(TTR)中的 2 个稳定遗传变异(R104H 和 T119M)进行了基因分型,并确定了基因型与转甲状腺素蛋白的血浆水平、甲状腺功能指标、血管疾病风险和预期寿命之间的关联。在平均 32 年的随访期间,有 10636 名参与者发生了血管疾病。我们共发现 321 名 T119M 杂合子(频率为 0.47%);未检测到 R104H。首先,与非携带者相比,杂合子的平均血浆转甲状腺素蛋白和甲状腺素水平分别升高 17%(26μg/ml)和 20%(19nmol/L)(P=0.007 和 P<0.0001),这表明该变异在普通人群中具有功能。其次,所有血管疾病的相应危险比分别为 0.70(95%置信区间,0.51-0.97)、心血管疾病为 0.85(0.59-1.23)、脑血管疾病为 0.45(0.25-0.81)、缺血性脑血管疾病为 0.47(0.25-0.88)和出血性中风为 0.31(0.04-2.22)。与非携带者相比,杂合子的脑血管疾病累积发病率随年龄的函数下降(P=0.005)。第三,与非携带者相比,所有原因导致的死亡、血管疾病和脑血管疾病导致的死亡、血管疾病诊断后的中位年龄,以及血管疾病的中位诊断年龄,在杂合子中增加了 5 至 10 年(P=0.002-0.05)。
这些结果与转甲状腺素蛋白遗传稳定性与降低脑血管疾病风险相关,以及与普通人群预期寿命延长相关的假说一致。